Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2582323 | 0.78 | — | — | |
| SCHEMBL30096746 | 0.78 | — | — | |
| SCHEMBL4453532 | 0.77 | SMN1; SMN2 (0.41) | SMN1; SMN2KMT2ACA14CA12ALDH1A1 | |
| SCHEMBL6882537 | 0.77 | TSHR (0.42) | CA14CA12CA1CA2 | |
| SCHEMBL6887935 | 0.75 | ALDH1A1 (0.42) | KMT2AALDH1A1 | |
| Chloroform SCHEMBL10642041 | 0.74 | — | — | |
| SCHEMBL7880308 | 0.73 | LMNA (0.36) | KMT2ACA14CA12 | |
| SCHEMBL11601602 | 0.72 | SMN1; SMN2 (0.34) | SMN1; SMN2KMT2ACA14CA1CA2 | |
| SCHEMBL1332029 | 0.71 | — | — | |
| SCHEMBL270012 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040254182-A1 | Enhanced propertied pharmaceuticals | ROHM AND HAAS COMPANY | 2004-12-16 | — | — | US | disclosed |
| EP-1272463-A1 | ENHANCED PROPERTIED PHARMACEUTICALS | ROHM AND HAAS COMPANY (US) | 2003-01-08 | — | — | EP | disclosed |
| WO-2002072559-A1 | PROCESS TO INTERMEDIATES FOR BIOLOGICALLY ACTIVE COMPOUNDS | ROHM AND HAAS COMPANY (US) | 2002-09-19 | — | — | WO | disclosed |
| US-20010039343-A1 | Process to intermediates for biologically active compounds | MULVIHILL MARK JOSEPH (US) | 2001-11-08 | — | — | US | disclosed |
| WO-2001056358-A2 | ENHANCED PROPERTIED PESTICIDES | ROHM AND HAAS COMPANY (US) | 2001-08-09 | — | — | WO | disclosed |
| WO-2001054481-A2 | ENHANCED PROPERTIED PHARMACEUTICALS | ROHM AND HAAS COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| WO-2001055082-A2 | INTERMEDIATES FOR BIOLOGICALLY ACTIVE COMPOUNDS | ROHM AND HAAS COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254182-A1 | Enhanced propertied pharmaceuticals | ABCB1, ABCB11, ABCG2 | SMN1; SMN2 1308/4885KMT2A 2133/4885CA14 1832/4885 |
| US-20010039343-A1 | Process to intermediates for biologically active compounds | DDT, CYP4X1, CYP1B1 | SMN1; SMN2 2861/4885KMT2A 3410/4885CA14 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.